MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome - UTU Research Portal

A1 Refereed original research article in a scientific journal

MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome

Authors: Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, van Daele PL, Dalm VASH, Drexhage HA, Versnel MA

Publisher: BMJ PUBLISHING GROUP

Publication year: 2014

Journal: Annals of the Rheumatic Diseases

Journal name in source: ANNALS OF THE RHEUMATIC DISEASES

Journal acronym: ANN RHEUM DIS

Volume: 73

Issue: 6

First page : 1052

Last page: 1059

Number of pages: 8

ISSN: 0003-4967

DOI: https://doi.org/10.1136/annrheumdis-2012-202552

Abstract

Conclusions The MxA assays were excellent tools to assess IFN type I activity in pSS, MxA-EIA being the most practical. MxA levels associate with features of active disease and are reduced in hydroxychloroquine-treated patients, suggesting the clinical applicability of MxA in stratifying patients according to IFN positivity.